Geovax Labs (Geovax Labs) Additional Paid-In Capital : $110.27 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Additional Paid-In Capital?

Geovax Labs's quarterly additional paid-in capital increased from Sep. 2023 ($105.86 Mil) to Dec. 2023 ($110.13 Mil) and increased from Dec. 2023 ($110.13 Mil) to Mar. 2024 ($110.27 Mil).

Geovax Labs's annual additional paid-in capital increased from Dec. 2021 ($68.73 Mil) to Dec. 2022 ($105.00 Mil) and increased from Dec. 2022 ($105.00 Mil) to Dec. 2023 ($110.13 Mil).

Geovax Labs Additional Paid-In Capital Historical Data

The historical data trend for Geovax Labs's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Additional Paid-In Capital Chart

Geovax Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

39.34

55.30

68.73

105.00

110.13

Geovax Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															105.27	105.50	105.86	110.13	110.27

Geovax Labs Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Geovax Labs Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GOVX:USA E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.